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Abstract
The chemotherapeutic agent cisplatin is renowned for its ototoxic effects. While hair 
cells in the cochlea are established targets of cisplatin, less is known regarding the 
afferent synapse, which is an essential component in the faithful temporal transmis-
sion of sound. The glutamate aspartate transporter (GLAST) shields the auditory 
synapse from excessive glutamate release, and its loss of function increases the vul-
nerability to noise, salicylate, and aminoglycosides. Until now, the involvement of 
GLAST in cisplatin-mediated ototoxicity remains unknown. Here, we test in mice 
lacking GLAST the effects of a low-dose cisplatin known not to cause any detectable 
change in hearing thresholds. When administered at nighttime, a mild hearing loss 
in GLAST KO mice was found but not at daytime, revealing a potential circadian 
regulation of the vulnerability to cisplatin-mediated ototoxicity. We show that the 
auditory synapse of GLAST KO mice is more vulnerable to cisplatin administra-
tion during the active phase (nighttime) when compared to WT mice and treatment 
during the inactive phase (daytime). This effect was not related to the abundance of 
platinum compounds in the cochlea, rather cisplatin had a dose-dependent impact 
on cochlear clock rhythms only after treatment at nighttime suggesting that cisplatin 
can modulate the molecular clock. Our findings suggest that the current protocols 
of cisplatin administration in humans during daytime may cause a yet undetectable 
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1 |  INTRODUCTION
Cisplatin (cis-diamminedichloroplatinum II, CDDP) is a 
highly effective chemotherapeutic agent commonly used in 
the treatment of solid tumors and several malignant tumors, 
such as those of the head and the neck, in adults and chil-
dren.1,2 Cisplatin is known to have numerous debilitating 
side effects such as permanent hearing loss, neurotoxicity, 
and nephrotoxicity.2,3 The impact of cisplatin on auditory 
function has been observed near half a century ago,4 and 
yet, is not receiving enough attention in current medical 
practice.5,6 The prevalence of hearing loss following cis-
platin treatment is dependent upon cumulative dose,5 and 
has been reported as being between 4% and 90% depending 
on factors such as age and gender of the patient, a combi-
nation of other ototoxic agent(s) or irradiation used, expo-
sure to concomitant noise, duration of the treatment, and 
administration methods.7 A study on North Americans 
showed that 18% have profound hearing loss, and 40% de-
velop tinnitus after increasing cumulative cisplatin doses.5 
Children generally show greater vulnerability to cispla-
tin-mediated hearing loss than adults.8-10 As hearing loss 
has recently been ranked fourth leading cause of years lived 
with disability,11 while also being an established risk factor 
for dementia,12 understanding the mechanisms underlying 
cisplatin-mediated ototoxicity is of major health relevance 
and of great need for the prevention and treatment of hear-
ing loss.
In humans and experimental animals, cisplatin-induced 
hearing loss usually impairs the high frequency regions of 
the cochlea and extends to lower frequencies with prolonged 
treatment. A variety of procedures have been used to iden-
tify the key structures causing hearing loss by cisplatin and 
found that marginal cells of the stria vascularis (SV), spiral 
ligament, the organ of Corti (OC), (primarily outer hair cells 
[OHC] and subsequently inner hair cells [IHC]), supporting 
cells and the spiral ganglion neurons (SGN) are particularly 
susceptible and prone to cisplatin retainment for a long pe-
riod of time.3,13,14 Cisplatin targets tumor proliferative cells 
through DNA damage.1 Since cochlear cells do not pro-
liferate, it is more reasonable that ototoxicity is caused by 
mitochondrial damage.15 A dominant pathway for cisplatin 
ototoxicity is NOX3 signaling, leading to the production of 
reactive oxygen species (ROS), which in turns induce in-
flammatory reactions promoting apoptotic and necrotic cell 
death.15,16
While the understanding of the actions of cisplatin on 
hair cell death has increased in the last decade, very little is 
known on the impact of cisplatin on the IHC/afferent neuron 
synapse, which dysfunction perturbs the propagation of au-
ditory information along the auditory nerve. Indeed, recent 
work has suggested that the most vulnerable elements in the 
auditory periphery are actually the cochlear nerve terminals 
rather than the hair cells or the stria vascularis.17,18 Even after 
noise exposures causing only transient threshold elevation, 
there can be significant loss of synaptic connections between 
the IHCs and the peripheral terminals of cochlear nerve fi-
bers, despite no loss of hair cells or persistent threshold 
elevation. Although threshold shift is a sensitive metric of 
hair cell damage, diffuse loss of IHC synapses, or their co-
chlear nerve fibers has to exceed 80%-90% before behavioral 
thresholds rise significantly and can reach 40%-50% without 
elevating thresholds of compound neural potentials such as 
the auditory brainstem responses (ABR).17 This type of au-
ditory neuropathy results from damage or loss of presynaptic 
ribbons, a structure in hair cells responsible for the release 
of neurotransmitters, such as glutamate at sub-millisecond 
temporal precision and maintenance of signal transmission.19 
This glutamatergic synapse is shielded by the glutamate as-
partate transporter (GLAST), which has been found in sup-
porting inner phalangeal cells (IPCs) cells surrounding the 
IHCs, fibrocytes in the spiral ligament and the spiral limbus, 
and satellite cells of the SGNs.20 Similar to the central ner-
vous system, GLAST limits the accumulation of extracellular 
glutamate, thereby preventing tonic activation of receptors 
and subsequent excitotoxicity.21 Consistently, mice lacking 
GLAST show greater hearing threshold shifts and synaptic 
damage than do wild-type (WT) mice after noise exposure,22 
as well as greater vulnerability to aminoglycoside and salicy-
late ototoxicity.23,24 As guinea pigs and rats are more suscep-
tible than mice to cisplatin-mediated ototoxicity,25 GLAST 
may potentially be involved in the protection of the synapse 
subjected to cisplatin treatment. Furthermore, since humans 
do not display GLAST expression in IPCs,26 GLAST KO 
mice may more closely reflect the vulnerability of the human 
synapse to auditory insults, and thus, facilitate the translation 
of preclinical findings to humans.
Another aspect poorly investigated, is the consideration of 
circadian aspects in the ability to mitigate cisplatin ototoxicity. 
The cochlea is indeed a highly circadian organ, with circadian 
rhythms of the protein PER2 as ample as what is found in 
the liver, and expressing elements of the core clock machinery 
damage to the auditory synapse, more so in already damaged ears, and severely  
impact auditory sensitivity in cancer survivors.
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such as Per1, Per2, Bmal-1, and Rev-erbα mainly in hair 
cells and SGNs.27 At the cellular level, oscillatory patterns 
propagate from the apex toward middle turns and cellular 
synchronicity within the cochlea requires the function of volt-
age-gated potassium channel and extracellular calcium.28 Two 
consequences from this auditory clock have been evidenced: 
first, the cochlea is more vulnerable at nighttime to noise dam-
age,29 a process that requires circulating glucocorticoids 30; 
second, the action of drugs (eg, dihydroxyflavone, a selective 
TrkB agonist, and dexamethasone) to protect from noise-dam-
age depending on the time-of-the-day, the TrkB agonist is ef-
fective when administered at nighttime, and dexamethasone 
at daytime.29,30 Thus, drugs may have a different impact de-
pending on the time-of-the-day when administered. Whether 
the ototoxic effects of cisplatin on the auditory system depend 
on the time-of-the-day is poorly known. Here, we evaluate the 
impact of GLAST loss of function after day or night cisplatin 
administration using a protocol of mild ototoxicity.
2 |  METHODS
2.1 | Experimental animals
All experimental procedures on animals were performed 
in accordance with the guidelines and the regulations of 
Karolinska Institutet and approved by the regional ethics 
committee (Stockholm's Norra Djurförsöksetiska Nämnd, 
N156/14 and N140/15).
GLAST KO mice31 and their WT littermates were ob-
tained from heterozygous (HET) crosses or from KO males 
crossed with HET females. Similar to what we previously 
reported,24 we observed a non-mendelian distribution in 
the progeny of crosses between heterozygous KO mice 
(n = 200): 29% wild-type animals, 54% heterozygous knock-
out animals, and 15% homozygous knockout animals. Two 
percent of the pups had an unclear genotype. Males and 
females aged between 2 and 3 months were pooled for this 
project, since separated genders did not present any signif-
icant differences and used for audiological, morphological, 
and molecular measurements. GLAST-CreERT2 transgenic 
mice32 were crossed to the Rosa26-tdTomato (tdTom) Cre-
reporter line (obtained from the Jackson Laboratory, B6.Cg-
Gt(Rosa)26Sortm14(CAG-tdTomato)Hze/J, JAX stock: 007914)33 
to generate GLAST-CreERT2;R26R-tdTom mice, in which 
CreERT2 is hemizygous and Rosa26-tdTom is either hetero-
zygous or homozygous. All animals were ≥8 weeks old at the 
onset of experiments. Genetic recombination was induced by 
a daily intraperitoneal injection of 2 mg of tamoxifen (Sigma, 
20 mg/mL in 1:9 ethanol: corn oil) for five consecutive days. 
PER2::LUC (mPer2Luc) mice34 were used in order to track 
PER2 bioluminescence from cochlear explants in the pres-
ence or absence of cisplatin treatment. All animals were in a 
C57BL/6J genetic background. Animals had ad libitum ac-
cess to food (Lactamin R34) and water. Temperature in the 
animal facility was maintained between 19 and 21°C and 
lights were on at 6:00 AM and off at 6:00 PM Work in dark-
ness was performed under red light.
2.2 | In vivo and in vitro drug treatment
For in vivo experiments, GLAST WT and KO male and fe-
male mice were used. Forty-nine mice (24 WT and 25 KO) 
underwent auditory measurements prior to the treatment 
(baseline measurements) and at the end of the treatment 
(24 hours and 2 weeks post). Cisplatin treated mice (479306, 
Sigma-Aldrich) received an intraperitoneal (i.p.) injection 
once-daily in a dose of 4  mg/kg (30  mg/kg, 200  mL/30  g 
body weight) (cisplatin diluted in 0.9% NaCl) for four con-
secutive days, either at daytime, at 09.00 AM (Zeitgeber time 
3, ZT3) or at nighttime at 09.00 PM (ZT15). Zeitgeber time is 
used for indicating the phase of an entrained circadian cycle 
in which ZT 0 is the time when lights are on and ZT 12 when 
the lights are turned off. Twelve mice (6 WT and 6 KO) were 
used as control animals since they were treated with saline 
(0.9% NaCl) for four consecutive days either at day or night-
time. GLAST WT and KO male mice (14 WT and 14 KO) 
were used for measuring the platinum compounds in the OC/
SGN, SV, and plasma 1 hour after one single i.p. cisplatin 
injection (4  mg/kg) either administered at daytime (08:00 
AM) or at nighttime (08:00 PM). For in vitro experiments, 
cisplatin dissolved in phosphate-buffered saline (PBS) was 
used in different concentrations of 40, 80, 160, 400, 800, and 
1600 nM. Final concentrations of cisplatin were made from 
a stock of 2 mM.
2.3 | Auditory measurements
Stimuli were generated using BioSigRP software which was 
connected to Tucker-Davis Technologies System III hard-
ware. For distortion product otoacoustic emissions (DPOAE) 
recordings, two independent signals were broadcast from a 
single multifunction processor (RX6) to two separate pro-
gramable attenuators (PA5). Each attenuator connected to a 
dedicated speaker driver (ED1) that played the stimulus over 
a dedicated electrostatic speaker (EC1). Sound from the two 
speakers merged in a custom made, ear-canal probe with a 
soft plastic tip for closed field stimulation. For ABR meas-
urements, the signal went from a processor to an attenuator. 
It was then fed to an amplifier (SA1) and output through an 
open field speaker (MF1).
Stimulus intensity was calibrated using a ¼-inch mi-
crophone and a conditioning preamplifier (4939 A 011 
and 2690 A 0S1, Brüel and Kjær) connected to an RX6 
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processor. For DPOAE stimuli the microphone was cou-
pled as closed field to the ear-canal probe and mimicked the 
location of the eardrum. For ABR stimuli the microphone's 
position approximated the location of an experimental 
animal's ear and had its membrane facing the open field 
speaker. Speakers were calibrated before the beginning of 
each experiment using a frequency sweep (4-32 kHz). The 
output was corrected to produce a flat spectrum at 100 dB 
SPL (open field speaker, ABR) and 70 and 80  dB SPL 
(closed field speakers, DPOAE).
Mice were anesthetized with a mixture of ketamine 
(ketaminol 50  mg/mL, Intervet, 511485) and xylazine 
(Rompun 20 mg/mL, Bayer, KP0A43D) (100 and 10 mg/
kg body weight, 200 µL/30 g, respectively) and placed in a 
custom-made acoustic enclosure with sound absorbing ma-
terial on the walls and ceiling (60 × 60 × 100 cm3). Body 
temperature was maintained at 36.5°C using a heating 
pad (HB 101/2 Panlab, Harvard Apparatus). Temperature 
was under control during each experiment by placing a 
thermometer under the mouse's body. We first recorded 
DPOAEs. In short, the acoustic coupler was inserted into 
the ear canal. A microphone (EK 23103, Knowles) inserted 
in the acoustic coupler with a preamplifier (ER-10B+, 
Etymotic Research) and connected to a processor (200 kHz 
sample rate) measured sound intensity in the ear canal. 
Each speaker played one of two primary tones (f1 and f2) 
and swept in 5 dB steps from 80 to 10 dB SPL (for f2). To 
avoid distortion of no physiological origin, stimulus levels 
were kept ≤80 dB SPL. The 2f1 − f2 distortion product was 
measured with f2  =  8, 12, 16, 24  kHz, f2/f1  =  1.25, and 
stimulus levels L1 = L2 + 10 dB SPL. DPOAE thresholds 
were defined as the lowest level of f1 required to produce a 
DPOAE ≥ −5 dB SPL.
Subsequently, we measured ABRs. Stainless-steel sub-
dermal needle electrodes were placed one at the head vertex 
(positive), one under the right ear pinna (negative), and the 
third one above the right leg (ground). ABRs were evoked by 
tone bursts (0.5 ms rise/fall time, 5 ms duration) of 8, 12, 16, 
and 24 kHz, presented 33.3 times per second. Signals were 
collected via a low-impedance head stage (RA4LI) connected 
to a preamplifier (RA4PA) and digitally sampled with a pro-
cessor (200 kHz sample rate). Responses to 1000 bursts were 
bandpass filtered at 0.3-3 kHz using BioSigRP and averaged at 
each intensity to determine the threshold. For each frequency, 
sound intensity was decreased from 90 to 5 dB SPL in 5 dB 
steps, until threshold was reached and confirmed with 2 or 
3 replicate measurements. Threshold was defined as the low-
est sound intensity with visually identifiable and reproducible 
waves. Wave 1 amplitude was determined as the difference 
between the first wave peak and its subsequent trough.
ABR and DPOAE measurements were performed 5-7 days 
prior to cisplatin or saline treatment (baseline), 24 hours and 
2 weeks after the last injection.
2.4 | Immunohistochemistry and 
quantification of synaptic receptors
For immunostaining, 2 weeks after the last administration 
of cisplatin or saline (control), mice underwent transcar-
diac perfusion with 4% of paraformaldehyde in PBS and 
cochleae were decalcified in 0.12 M of ethylenediaminetet-
raacetic acid (EDTA) for 2-3 days. For the demonstration 
and  quantification of presynaptic ribbons, postsynaptic 
glutamatergic AMPA-receptors (GluA2) and their cou-
pling, cochlear surface preparations were micro-dissected 
and stained for (a) C-terminal binding protein 2 (mouse 
(IgG1) anti-CtBP2, 612044 from BD-Biosciences, used at 
1:200), to quantify presynaptic ribbons; (b) Glutamate re-
ceptor subunit A2 (mouse (IgG2a) anti-GluA2, MAB397 
from Millipore, used at 1:1000), to quantify postsynap-
tic receptors and (c) rabbit anti-Myosin VIIa, (25-6790 
from Proteus Biosciences, used at 1:200) to delineate the 
hair cell bodies. Primary antibody incubations were per-
formed overnight at 37°C, followed by 2 hours incubation 
at 37°C with secondary antibodies coupled to Alexa fluor 
dyes (IgG1 goat anti-mouse AF568 at 1:500, IgG2a goat 
anti-mouse AF488 at 1:500 and IgG donkey anti-rabbit 
AF647 at 1:200), correspondingly. The cochlear pieces 
were mounted in Vectashield with DAPI, cover-slipped 
and sealed with nail polish. Cochlear frequency mapping 
was then performed using a custom plug-in to ImageJ from 
NIH (Measure_Line.class from the Liberman laboratory at 
the Eaton-Peabody Laboratory). This gave the total length 
of the cochlea and their respective frequency points and 
was used as a guide obtaining confocal images for discrete 
frequency regions (6, 8, 12, 16, 24, 32, 48, and 64  kHz) 
along the length of the cochlea. Confocal z-stacks (20-
40), with dimensions 1024 × 1024 and 16-bit image, along 
discrete regions of the basilar membrane were made with 
a 63× oil immersion objective (NA1.40) on a Zeiss LSM 
880 confocal microscope. A z-stack of 642 nm and inter-
val 1 µm was used to capture all synaptic structures of at 
least 10 hair cells. Image stacks were analyzed using Imaris 
software (x64 9.2.0, Bitplane AG, Zurich, Switzerland) for 
the number of ribbons or postsynaptic receptors as well 
as for their synaptic pairing. Number of ribbons per IHC 
was confirmed in ImageJ software. For assessing the total 
number of ribbons or postsynaptic GluA2 puncta per IHC, 
surface and masking properties were identified. Then, the 
region of interest (approximately 10 hair cells) was tagged 
for counting by using the “spots” function. After adjust-
ing for the thresholds, puncta with pixel intensities greater 
than 0.6 µm on an 8-bit scale (0-255) were counted. For de-
termining the synaptic pairing, “distance transformation” 
and “spot co-localization” was used. The threshold/dis-
tance between the spots was set to 0.7-1 µm. The volume 
of each puncta was determined by using different spot sizes 
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function. Then, the same procedure as for the number of 
puncta was followed in order to specify the size. The group 
where a sample belonged to, was blinded to the analyst.
2.5 | Detection of GLAST expression 
in the cochlea
To visualize the expression of GLAST in cochlear tissue, 
GLAST-dtTom mice were intracardially perfused with PBS 
followed by 4% of paraformaldehyde dissolved in PBS prior 
to removing the cochlea. The cochleae were decalcified 
as described above, soaked in 20% of sucrose in PBS for 
24 hours in 4°C for cryoprotection. After embedding in 20% 
of gelatin, the cochlear specimens were quickly deep fro-
zen and stored in −70°C. Serial mid-mediolar sections with 
thickness of 14 µm were cut on a cryostat (HM 500 M, Zeiss) 
at −20°C. Prior to the staining procedure, the sections were 
air dried for 2 hours and rinsed in PBS at 37°C for 20 min-
utes in order to remove the gelatin. The sections were incu-
bated with 5% of normal goat serum in 0.3% of Triton-X in 
PBS for 30 minutes at room temperature followed by over-
night incubation with calbindin antibody (1:400, ab11426, 
Abcam). Following the rinsing in PBS, the sections were 
incubated with goat anti-rabbit secondary antibody (Alexa 
488, A11008, Thermo fisher) for 2 hours. The sections were 
rinsed with PBS and incubated with Hoechst 33258 at 2 µg/
mL (H3569, Thermo fisher) for 20 minutes. Following sub-
sequent wash in PBS, the slides were mounted with prolong 
anti-fade mounting medium (Thermo fisher). The slides 
were analyzed under a Zeiss LSM 880 confocal microscope 
at different magnifications and photographed.
2.6 | Induced-coupled plasma Mass 
spectrometry
Platinum levels were measured 1  hour after one single in-
jection of 4 mg/kg cisplatin, administered either at daytime 
(08.00 AM) or at nighttime (08.00 PM) from the OC includ-
ing SGNs, SV and blood from GLAST WT and KO male 
mice (N = 28). Mice were then euthanized by isoflurane in-
halation, followed by decapitation. In order to collect plasma 
samples, blood was obtained from the trunk after decapita-
tion. The cochlear compartments were snapped frozen in dry 
ice and kept at −80°C until induced-coupled plasma Mass 
spectrometry (ICP-MS) measurements were made. The blood 
was centrifuged in order to separate plasma which was then 
kept at −80°C until the platinum analysis. The procedure of 
Breglio et al,14 was used for the analysis and quantification of 
platinum compounds. The data were presented as the concen-
tration of platinum compounds normalized to protein concen-
tration of each tissue.
2.7 | Organotypic cultures and PER2::LUC 
oscillations
Adult cochleae were dissected from PER2::LUC male and 
female knock-in mice (N  =  46) and cultured organotypi-
cally on a membrane (Millipore, PICMORG50) as previ-
ously described.29 Cochleae, dissected free of bone and 
SV, were kept in culture for a minimum of 6  days whose 
morphology has been previously characterized.28 Isolated 
cochleae from PER2::LUC mice (8-12 weeks of age) were 
used. The bioluminescence emission from the cochlea was 
measured for 1 minutes every 10th minute with Lumicycle, 
a microplate luminometer equipped with photomultiplier 
tubes (Actimetrics, Wilmette, IL). Parameters of PER2::LUC 
rhythmicity (amplitude, phase, and period) were quantified. 
Amplitude and phase were analyzed using Origin software 
8.1 SR1 (Microcal Software, Northampton, MA, USA) and 
period was identified by using the Lumicycle Analysis pro-
gram from where we extracted the raw values. Data from 
each recording trace was first normalized by subtracting the 
24  hours baseline drift from the raw data. The amplitude 
was calculated as the difference between the highest (peak) 
and the lowest (trough) photon count within one cycle. The 
calculation was performed from trough-to-peak and from 
peak-to-trough, thus, giving two values (half-cycles) within 
one cycle. For each amplitude data point, three half-cycles 
(1.5 cycles) were used for amplitude analyses. The very first 
peak after culture start was not used. Phase was determined 
as maximum (peak) luminescence between 24 and 48 hours 
(peak between day 1 and 2) of recording. The average peak 
time of each treatment group was calculated and statistically 
compared with the respective sham group. The period of one 
complete cycle was defined as the time between two consecu-
tive peaks (ie, the highest photon count within one cycle) and 
five consecutive peaks were used for averaging periods. Ex 
vivo cultures were treated with cisplatin or PBS (control) ei-
ther at the trough (day 3 of culture) or at the peak (day 3.5) of 
the oscillation. These two time points were chosen since they 
correspond to the peak and trough levels of cochlear PER2 
protein expression, slightly delayed from peak (ZT12) and 
trough (ZT0) Per2 mRNA levels. The drug was washed out 
3 days later, when fresh culture medium was added. This was 
not performed immediate after cisplatin treatment to avoid 
confounding resetting effects upon medium change, known 
to synchronize oscillations in culture.
2.8 | Statistical analysis
One, two or three-way ANOVA with Sidak's or Tukey's post 
hoc were used for statistical analysis (Prism version 8.0, 
GraphPad software). Difference, which was below 0.05, con-
sidered significant and depicted with an asterisk (*). All data 
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points are shown as mean values ± SEM. Reported n is the 
number of animals/samples analyzed.
3 |  RESULTS
3.1 | Expression of GLAST in the cochlea
We first used dtTom (red) reporter mice under the control 
of the GLAST promoter to determine where GLAST is ex-
pressed in the cochlea. Expression was found in the support-
ing cells (inner border and inner and outer phalangeal cells) 
surrounding the inner hair cells, the satellite cells surrounding 
the spiral ganglion neurons, the fibrocytes of the spiral liga-
ment and in the fibrocytes of the spiral limbus (Figure S1). 
Staining was not observed in the stria vascularis, outer hair 
cells or the interdental cells of the spiral limbus. The Purkinje 
cells of the cerebellum were used as a positive control and 
high expression was found in these cells (data not shown).
3.2 | Nighttime administration of cisplatin 
causes hearing loss in GLAST KO mice
To investigate the circadian impact of cisplatin on auditory 
function, we applied a 4 mg/kg/day dose of the drug for four 
consecutive days during either daytime (ZT3) or nighttime 
(ZT15). Baseline values for ABR thresholds did not differ 
between GLAST KO and WT mice (with Sidak's post hoc 
analysis, P = .051-.44 for all frequencies tested, Figure S2A). 
F I G U R E  1  Cisplatin administration at nighttime affects hearing threshold shifts. A, ABR threshold shifts from GLAST WT (red open circles) 
and GLAST KO (red filled diamonds) mice exposed to 4 mg/kg cisplatin for 4 days, at daytime (09.00 AM), were measured 24 hours (left panel) 
and 2 weeks (right panel) after the last injection. Results are mean values ± SEM; n = 10-13. *P < .05; **P < .01; ***P < .001; two-way ANOVA 
with Sidak's post hoc analysis. B, DPOAE threshold shifts from GLAST WT and KO mice 24 hours (left panel) and 2 weeks (right panel) after 
day cisplatin administration. Results are mean values ± SEM; n = 10-13. *P < .05; **P < .01; ***P < .001; two-way ANOVA with Sidak's post 
hoc analysis. C, ABR threshold shifts from WT (blue open circles) and KO (blue filled diamonds) mice exposed to 4 mg/kg cisplatin for 4 days, at 
nighttime (09.00 PM), measured 24 hours post (left panel) and 2 weeks post (right panel). Results are mean values ± SEM; n = 10-12. *P < .05; 
**P < .01; ***P < .001; two-way ANOVA with Sidak's post hoc analysis. Stars depicted above KO at 8 and 24 kHz showed statistical significance 
compared to WT. D, DPOAE threshold shifts from WT and KO mice 24 hours post (left panel) and 2 weeks post (right panel) after the last night 
injection. Results are mean values ± SEM; n = 10-12. *P < .05; **P < .01; ***P < .001; two-way ANOVA with Sidak's post hoc analysis
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F I G U R E  2  Effects of cisplatin on ABR Wave 1 amplitude of GLAST WT and KO mice. Quantification of ABR Wave 1 amplitude of 
GLAST WT (open circles) and GLAST KO (filled diamonds) mice at baseline levels (left panel), 2 weeks after day cisplatin administration (middle 
panel), and 2 weeks after night cisplatin administration (right panel) at 8, 12, 16, and 24 kHz. Results are mean values ± SEM; n = 10-13. *P < .05; 
**P < .01; ***P < .001; two-way ANOVA with Sidak's post hoc analysis. Stars above KO line at specific dB levels depict statistical significance 
compared to WT mice
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Similarly, DPOAE thresholds did not differ between the two 
genotypes at baseline level (with Sidak's post hoc analysis, 
P = .93-.99 for all frequencies tested, Figure S2B). We next 
assessed ABR threshold shifts 24 hours and 2 weeks post day 
or night cisplatin administration from GLAST WT against 
KO mice. While the ANOVA revealed an effect of genotype 
2 weeks post day treatment (F(1, 68) = 7.026, P = .01), no dif-
ferences were found in Sidak's post hoc analyses (2 weeks 
post day treatment, WT vs KO: P =  .086-.9976 for all fre-
quencies tested; Figure 1A). We assessed DPOAE threshold 
shifts 24 hours and 2 weeks post day or night cisplatin ad-
ministration from WT and KO mice and we found a transient 
effect of genotype 24  hours post day treatment (two-way 
ANOVA, 24 hours post day treatment: Genotype Factor F(1, 
92) = 14.17, P = .0003; Frequency Factor F(3, 92) = 0.1349, 
P  =  .94; with statistical difference between WT and KO 
at 12 kHz after Sidak's post hoc analysis, P = .03), but not 
2  weeks after (two-way ANOVA, 2  weeks post day treat-
ment: Genotype Factor: F(1, 92) = 0.817, P = .368; Frequency 
Factor: F(3, 92) = 0.323, P = .8; Figure 1B), suggesting that 
DPOAEs from WT mice show a transient decrease after day 
cisplatin treatment, which recovers when assessed 2 weeks 
post treatment. In contrast, greater ABR threshold shifts were 
found in KO mice compared to WT 2 weeks after night ad-
ministration (two-way ANOVA, 2 weeks post day: Genotype 
Factor: F(1, 88) = 33.28, P < .0001; Frequency Factor: F(3, 88) 
= 7.557, P = .0001; Figure 1C), in spite of unaltered DPOAE 
threshold shifts (two-way ANOVA, Genotype Factor: F(1, 
88) = 1.58, P  =  .212; Frequency Factor: F(3, 88) = 0.1331, 
P = .94; Figure 1D). When comparing day vs night treatment, 
we could not detect any difference in ABR threshold shifts. 
Table S1 provides the summary statistics from a three-way 
ANOVA evaluating the threshold shifts measured 2 weeks 
post day or night noise trauma in GLAST WT or KO mice. 
While an effect on time and frequency was detected (three-
way ANOVA, Frequency Factor: F(3, 156) = 11.97, P < .0001; 
Genotype Factor: F(1, 156) = 32.87, P < .0001), no effect of 
time of treatment was revealed (three-way ANOVA, Time 
of treatment Factor: F(1, 156) = 1.22, P = .27). These findings 
suggest that nighttime administration of cisplatin in GLAST 
KO mice causes mild hearing loss.
3.3 | GLAST KO mice display lower ABR 
Wave 1 amplitude at baseline, which is not 
further worsened by cisplatin administration
We previously reported that GLAST KO mice display near 
50% reduction in the amplitude of the ABR Wave 1 in the ab-
sence of any noise or ototoxic drug exposure.35 We thus quan-
tified the ABR Wave 1 amplitude at baseline and 2 weeks 
after the last day or night cisplatin administration between 
WT and KO mice. Consistent with our former findings, 
GLAST KO mice showed reduced ABR Wave 1 amplitudes 
when compared to WT mice (two-way ANOVA, P < .0001 
for all frequencies tested, Figure  2). When we compared 
the Wave 1 amplitude at the highest stimulus (90 dB Sound 
Pressure Level-SPL) of the respective WT or KO mice across 
baseline, 2 weeks post day or night treatment (Figure S3), no 
changes were found 24 hours or 2 weeks post day or night 
cisplatin treatment when compared to their respective base-
line at any frequency (P  >  .17), with the exception of the 
24 kHz in the KO mice which were slightly elevated 2 weeks 
after day treatment when compared to baseline (P  =  .04, 
Figure S3).
3.4 | Presynaptic ribbons and synapses are 
more vulnerable to cisplatin at nighttime in the 
absence of GLAST
Cochlear synaptopathy is inferred from reduced ABR Wave 
1 amplitude in the absence of changes in hearing thresholds.36 
We thus assessed the abundance of presynaptic ribbons and 
paired synapses in saline treated GLAST WT and KO mice 
and confirmed that the number of ribbons remained unaf-
fected in KO mice (two-way ANOVA, Genotype factor: F(1, 
147) = 0.097, P = .755; Frequency Factor: F(7, 147) = 23.30, 
P < .0001, Figure 3A,B), whereas there was a decrease in the 
proportion of paired synapse (two-way ANOVA, Genotype 
factor: F(1, 44) = 34.75, P < .0001; Frequency Factor: F(7, 44) 
= 6.335, P <  .0001, Figure 3A,C), most evident at 12 and 
16 kHz (P = .0006 and .003, respectively), in line with the 
reduced ABR Wave 1 amplitude (Figure 2).
Consistent with a greater impact on hearing thresholds 
after night cisplatin administration, a greater loss of pre-
synaptic ribbons and synaptic pairing was found in GLAST 
KO mice when compared to WT (Figure 3). While  loss of 
presynaptic ribbons was evident in GLAST KO mice at 12 
and 24  kHz 2  weeks after night cisplatin treatment (two-
way ANOVA, Genotype factor: F(1, 141) = 27.50, P < .0001; 
Frequency Factor: F(7, 141) = 10.79, P < .0001), such differ-
ences were not found in day treated animals, where instead 
an increase in ribbons could be found in the KO treated 
during daytime (two-way ANOVA, Genotype factor: F(17, 
149) = 10.34, P = .0016; Frequency Factor: F(7, 149) = 8.519, 
P < .0001; with Sidak's post hoc analysis, P = .17-.99 across 
all frequencies; Figure  3B), consistent with the greater in-
crease in Wave 1 amplitude shown in Figure S3. Notably, 
there was a significant reduction of synaptic pairing (cou-
pled synapses) in GLAST WT mice, at 16  kHz both after 
day and night cisplatin administration when compared to WT 
saline mice (two-way ANOVA with Sidak's post hoc test, day 
treatment: P = .04, night treatment: P = .01, Figure 3C). On 
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F I G U R E  3  Cisplatin treatment at nighttime influences synaptic ribbons and abolishes synaptic coupling. A, 3D Imaris illustration from 
confocal imaging of presynaptic ribbons (red dots), postsynaptic GluA2 (green dots), and their synaptic pairing in 5 IHCs labeled with Myosin-
VIIA (blue) at 12 kHz, in WT (upper) and KO (below) mice, from control (left panel), day treated group (middle panel), and night treated group 
(right panel). B, Quantification of the amount of presynaptic ribbons in each IHC, along the whole cochlea of WT and KO mice, 2 weeks after 
saline (control) injections (left panel), day cisplatin administration (middle panel), and night cisplatin administration (right panel). Results 
are mean values ± SEM; n = 4-13. *P < .05; **P < .01; ***P < .001; two-way ANOVA with Sidak's post hoc analysis. C, Quantification of 
number of paired synapses per IHC across the length of the cochlea of WT and KO mice, in saline, day and night treated group. Results are mean 
values ± SEM; n = 1-6. *P < .05; **P < .01; ***P < .001; two-way ANOVA with Sidak's post hoc analysis
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the contrary, the impact of night cisplatin administration was 
more evident on synaptic coupling of GLAST KO, with a near 
complete loss at 12, 24, and 32 kHz compared to WT (two-
way ANOVA with Sidak's post hoc test, P = .04, P = .0002, 
and P  =  .01, respectively; Figure  3C), something that was 
not depicted in day treated animals (two-way ANOVA with 
Sidak's post hoc test, P > .94 on all frequencies, Figure 3C).
3.5 | Circadian effects on synaptic 
vulnerability to cisplatin
To assess the circadian impact on ribbon counts and synaptic 
pairing, we performed a three-way ANOVA comparing the 
impact of the genotype, the time of treatment, and the fre-
quency along which ribbon counts or synapse pairing was 
evaluated (Table S1). While ribbon counts were impacted in 
terms of frequency and time of treatment (three-way ANOVA, 
Frequency Factor: F(7, 290) = 17.03, P  <  .0001; Time of 
Treatment Factor: F(1, 290) = 13.92, P = .0002), genotype had 
a strong tendency, but without reaching significance (three-
way ANOVA, Genotype Factor: F(1, 290) = 3.136, P = .08). In 
contrast, synapse pairing differed along frequencies, between 
genotypes and by time of treatment (three-way ANOVA, 
Frequency Factor: F(7, 91) = 2.276, P = .04; Genotype Factor: 
F(1, 91) = 25.61, P < .0001; Time of Treatment Factor: F(1, 91) 
= 4.280, P = .04). Overall, the impact of cisplatin was greater 
on synapse pairing rather than on the synaptic ribbon alone, 
whereby in absence of glutamate buffering capacity (GLAST 
KO), administration during the active phase caused a dra-
matic reduction of coupled IHC/afferent neuron synapses. 
These findings suggest that GLAST may confer a protective 
role against circadian-dependent cisplatin injuries on the au-
ditory synapse.
3.6 | Cisplatin bioavailability in the cochlea 
is not influenced by the time-of-the-day
The greater impact of cisplatin on hearing thresholds and 
synaptic loss after night administration may be due to 
greater bioavailability when compared to day administra-
tion. We performed a pharmacokinetic analysis of cisplatin 
bioavailability in the SV and the combination of OC with 
SGN, 1 hour after day or night administration using ICP-MS. 
Consistent with greater renal and liver clearance during 
the active phase, measurements in the blood showed lower 
abundance of platinum compounds after night administra-
tion when compared to day administration, and the absence 
of GLAST function did not impact the bioavailability of 
circulating platinum (two-way ANOVA, Genotype factor: 
F(1, 24) = 0.258, P  =  .615; Time-of-the-day Factor: F(1, 24) 
= 31.75, P  <  .0001; Figure  4A). Interestingly, in cochlear 
compartments (eg, OC/SGN and SV), platinum compounds 
were equally available after day or night treatment, irrespec-
tively of GLAST function (two-way ANOVA, OC/SGN: 
Genotype factor: F(1, 24) = 0.523, P = .476; Time-of-the-day 
Factor: F(1, 24) = 0.057, P = .812; SV: Genotype factor: F(1, 
23) = 0.001, P = .97; Time-of-the-day Factor: F(1, 23) = 0.19, 
P = .66; Figure 4B,C). These findings suggest that the dam-
age in the cochlea after night cisplatin administration is not 
due to greater levels of cisplatin being present in the cochlear 
tissues.
3.7 | Effects of cisplatin on cochlea 
PER2::LUC rhythms ex vivo
The differential impact of cisplatin on the cochlea after 
day or night administration, prompted independent of 
F I G U R E  4  Differential platinum accumulation in the blood and the cochlear compartments. A, Platinum concentration in the plasma of 
GLAST WT (patterned bar) and GLAST KO (filled bar) mice, collected 1 hour after single cisplatin injection at daytime (08.00 AM) and at 
nighttime (08.00 PM). Platinum concentrations are normalized to protein concentration. Results are mean values ± SEM; n = 6-8. *P < .05; 
**P < .01; ***P < .001; two-way ANOVA with Sidak's post hoc analysis. Platinum concentrations in microdissected cochlear compartments as 
(B) OC/SGN and (C) stria vascularis from WT and KO mice. Results are mean values ± SEM; n = 6-8. *P < .05; ***P < .001; two-way ANOVA 
with Sidak's post hoc analysis
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bioavailability us to evaluate whether cisplatin could directly 
modulate cochlear clock rhythms. More specifically, we 
tested whether cisplatin affects the period of the oscillations 
(the interval between two reference points), the phase (re-
flecting a change in the peak time of synchronous cell oscil-
lations) and the amplitude (reflecting either a change in PER2 
expression or altered synchrony). Cochlear explants from 
PER2::LUC reporter mice, cultured for a period of 6-9 days, 
were exposed for a duration of 3 days to six different doses of 
cisplatin (40, 80, 160, 400, 800, and 1600 nM), applied either 
at the trough of the oscillations at day 3 of the culture (day 
administration) or at the peak of the oscillations, at day 3.5 
of the culture (night administration) in the absence of presyn-
chronization. Day cisplatin treatment did not show any ef-
fect on PER2 rhythms on the amplitude (one-way ANOVA, 
F(6, 27) = 0.794, P = .582), phase (one-way ANOVA, F(6, 30) 
= 0.65, P =  .69), and period (one-way ANOVA, F(6, 24) = 
1.214, P  =  .333, Figure  5A-C). In contrast, night cisplatin 
administration caused a decrease in the amplitude (one-way 
ANOVA, F(6, 29) = 5.505, P = .0007) and delay in the phase 
(one-way ANOVA, F(6, 31) = 3.769, P = .006), and the period 
(one-way ANOVA, F(6, 29) = 3.793, P = .0065) (Figure 5D-
F). These findings illustrate that cisplatin directly impacts on 
clock function in the cochlea when administered at nighttime, 
but not at daytime, and provides evidence of a direct relation-
ship between cisplatin and clock rhythms.
4 |  DISCUSSION
The present findings demonstrate a contribution of glutamate 
homeostasis in the circadian vulnerability to cisplatin-medi-
ated ototoxicity in mice, and more importantly, the afferent 
synapse, which appears more sensitive in glutamate trans-
porter deficient mice when cisplatin is administered dur-
ing the active phase (nighttime). Assuming this circadian 
ototoxic vulnerability would hold true in humans, who are 
diurnal unlike mice, this would suggest a greater risk for de-
veloping hearing loss and synaptopathy when treated during 
daytime. As the human inner phalangeal cells, which are the 
F I G U R E  5  Differential effects of cisplatin on PER2::LUC circadian rhythms in the cochlea ex vivo. A, Cisplatin dose response in amplitude 
expressed as percentage change, phase shift (hour) and period (hour) of PER2::LUC ex vivo cochleae treated at the trough of the oscillations 
(daytime). PBS was used as a control. Cisplatin administration was followed by washing out period. Results are mean values ± SEM; n = 3-9. 
*P < .05; **P < .01; ***P < .001; one-way ANOVA with Sidak's post hoc analysis. B, Cisplatin dose curve in amplitude (%), phase shift 
(hour) and period (hour) of PER2::LUC ex vivo cultures treated at the peak of the oscillations (nighttime). PBS was used as control. Cisplatin 
administration was followed by adding fresh medium. Results are mean values ± SEM; n = 3-9. *P < .05; **P < .01; one-way ANOVA with 
Sidak's post hoc analysis
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supporting cells surrounding the auditory afferent synapse, 
lack EAAT1,26 the homolog of rodent GLAST, the human 
synapse may thus display some of the vulnerability features 
reported here in the GLAST KO mice treated with cisplatin. 
Since ototoxicity is a major side effect from cancer treat-
ments using cisplatin,15 our study suggests that chronop-
harmacological approaches to cancer treatment may prove 
beneficial to decrease side effects, as exemplified with clini-
cal trials using chronomodulated infusion of oxaliplatin, an 
analogue of cisplatin.37,38 Given the leading contribution of 
hearing loss in years lived with disability,39 considering the 
time-of-the-day in cancer treatments using cisplatin may not 
only increase the likelihood of success, but also decrease side 
effects that have a non-negligible impact on surviving pa-
tient's life quality.
The increased vulnerability of the mouse auditory syn-
apse to cisplatin administration at nighttime may stem from a 
preexisting cochlear synaptopathy, as defined by a near 50% 
lower ABR Wave 1 amplitude and reduced paired synapses 
in normal hearing GLAST deficient mice in the absence of 
any ototoxic insult. On the contrary, cochleae with normal 
glutamate buffering abilities are less vulnerable and not 
equally subjected to circadian influences. In humans, there is 
evidence that patients with existing hearing deficits are more 
vulnerable to cisplatin ototoxicity.13,40 Thus, auditory screens 
prior to cancer treatment could identify individuals at risk for 
greater auditory damage. This would be even more relevant 
in children, who show more severe ototoxicity compared to 
adults.41 However, as severe neuropathy cannot be captured 
by conventional audiometry,42 new methods to diagnose 
damages at the auditory synapse are required.
Indeed, the decline in paired synapses in GLAST KO 
mice after night cisplatin administration did not correlate 
with changes in Wave 1 amplitude, suggesting that there is 
not always a direct relationship between synaptic status and 
Wave 1 amplitude, as previously suggested.36,43 Indeed, there 
have been debates on how reliable Wave 1 amplitude is as an 
indirect measure of synaptopathy in rodents and humans.44 
In animals, the lack of clear direct relationships between syn-
apse status and Wave 1 amplitude may be due to the type of 
trauma, filter settings, processor, and type of anesthetics used 
during ABR measures. Alternative methods to assess synap-
topathy are under way, such as ABR latency,45 the envelope 
following response (EFR),44,46 and the middle ear muscle re-
flex.47 GLAST KO mice may prove useful as a model to test 
these methods and develop new technologies.
The greater vulnerability to cisplatin-mediated ototoxic-
ity at nighttime was not related with drug bioavailability in 
cochlear compartments. Platinum compounds were found 
lower in the blood during the active phase probably due to 
greater liver detoxification and renal clearance during night-
time. However, the equally abundant platinum compounds 
in the cochlea after day or night cisplatin administration, 
irrespective of GLAST function, suggest a greater uptake at 
nighttime. Differences in drug uptake in the cochlea depend-
ing on the time-of-the-day have never been investigated, but 
the recent findings that the blood-brain barrier is under cir-
cadian control48 suggest that the blood labyrinth barrier may 
also subjected to such regulations.
Our findings, however, contrast those previously reported 
in Fischer 344 rats, where cisplatin treatment (12  mg/kg) 
within six groups treated at different time points around the 
clock caused greater hearing damage and OHC loss at higher 
frequencies at daytime.49 This greater vulnerability to ototox-
icity in rats correlates with greater lethality when cisplatin 
is administered during their inactive phase (daytime) com-
pared to their active phase.50 In contrast, antibiotic-mediated 
ototoxicity, influenced by circadian rhythms, appeared to be 
more damaging when administered at nighttime in Sprague-
Dawley rats, which is consistent with our findings.51,52 
Moreover, PER1/2 KO mice showed higher toxicity, in-
creased tumor volume and reduction of body weight, 2 weeks 
after 10 mg/kg of cisplatin administered at nighttime, with 
an enhancement in immune response probably due to a dis-
rupted clock.53 As different circadian responses to auditory 
insults appear to occur depending on the species and strains, 
the circadian impact of cisplatin-mediated toxicity in humans 
remains to be established.
There are several limitations to be acquainted in the pres-
ent study. First, we did not examine the endocochlear poten-
tial after the day and night cisplatin treatment. Indeed, the SV, 
which is the generator of the endocochlear potential that drives 
current through the hair cells, cumulates platinum compounds 
more than the OC and the SGNs14—something we could not 
observe here since OC and SGNs were sampled together. 
Second, GLAST protein is not only expressed in IHC/synapse, 
but also in satellite cells surrounding SGNs, and in spiral lim-
bus fibrocytes.54 Thus, the vulnerability of GLAST KO mice 
to cisplatin at nighttime may not be restricted to the synapse. 
Third, while we observe that cisplatin affects PER2 oscilla-
tions only when administered at the peak expression (night-
time), the molecular mechanisms underlying the regulation of 
clock rhythms by cisplatin remain unknown. Since it is well 
established that cisplatin impacts the mitochondria,3 and that 
mitochondrial function is an essential element of clock regu-
lation,55 cisplatin may impact clock function via altered mito-
chondrial metabolism at a specific times-of-the-day. Reversely, 
it could also be that the circadian expression of mitochondrial 
genes in the cochlea such as Sod2 and Lrp2, which peak at 
nighttime in the cochlea,30 could render the cochlea more vul-
nerable at nighttime. Indeed, should the function of the hearing 
organ be already subjected to high metabolic demand during 
the active phase, there would not be enough capacity for trig-
gering appropriate damage response mechanisms. Since these 
two genes are strongly associated with ototoxicity in humans,56 
future studies will need to address both genetic and circadian 
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impacts on cisplatin-mediated ototoxicity. While the current 
study does not directly address the mechanism(s) underlying 
the circadian vulnerability of the cochlea to cisplatin, our pre-
vious data evidencing the role of the suprachiasmatic nucleus 
(SCN) and adrenal-derived glucocorticoids in the increased 
vulnerability to noise trauma at nighttime30 offers a frame-
work for the design of a chronopharmacological treatment 
with repeated cisplatin administration.14 The clock in the co-
chlea is under the control of the SCN, which electrolytic lesion 
suppresses the rhythmic expression of core clock genes and 
protects from night noise trauma.30 Downstream of the SCN, 
are the adrenal glands that use glucocorticoids as a powerful 
synchronizer of peripheral clock rhythms.30 Their surgical re-
moval also protects from night noise exposure, however, only 
affects the rhythmicity of near 22.5% of circadian genes in the 
cochlea, some of which are related to inflammation.30 Since 
our previous data shows that SCN lesions or adrenalectomy 
are protective, a direct test would require surgical procedures 
in GLAST KO mice. Since these show near 50% mortality at 
birth, a conditional (cochlea or support cell specific) GLAST 
KO will be necessary to determine the contribution of clock 
elements in the protection to cisplatin-mediated ototoxicity.
Cisplatin ototoxicity poses a serious problem in cancer 
survivor's daily life due to hearing impairment.57 Major 
efforts have been made to find treatment strategies to re-
duce the side effects of cisplatin and other chemotherapeu-
tic agents,58 however, the different molecular and cellular 
mechanisms involved in cisplatin-induced hearing loss 
illustrate the complexity of this condition, making it dif-
ficult for an appropriate otoprotective agent to be found. 
One promising but underappreciated approach is the as-
sessment of chronopharmacological approaches and how 
these could potentially reduce the side effects of anticancer 
drugs, while improving their efficacy,59 as it has been ex-
emplified by oxaliplatin, a cisplatin derivative, widely used 
for the treatment of colorectal cancer in humans.37,38 Given 
the impact of time-of-the-day and cochlear function, treat-
ing cancer patients at the right time-of-the-day may prove 
useful not only for improving survival rates, but also for 
long-term life quality.
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